' 
![]()
SCIENTIFIC SCORE
Questionable
Based on 6 Researches
6.5
USERS' SCORE
Good
Based on 8 Reviews
8.5
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Vitamin D3 (as Cholecalciferol)
125 mcg
625%
Top Medical Research Studies
8
Vitamin D improves heart disease factors
The Effect of Vitamin D Deficiency Treatment on Lipid Profile and C-reactive Protein in Patients with Ischemic Heart Disease: Double-blind Randomized Clinical Trial.
Direct relevance to cardiovascular health
We conducted a double-blind, randomized clinical trial to see how treating vitamin D deficiency could influence heart health, particularly in patients with ischemic heart disease (IHD). In our study, 44 IHD patients aged 40 to 65 were treated with either vitamin D or a placebo to assess changes in their lipid profiles and C-reactive protein (CRP) levels.
Our findings revealed that participants who received vitamin D supplementation showed notable improvements. Specifically, we observed higher levels of high-density lipoprotein cholesterol (HDL-C)—often referred to as the "good" cholesterol—and lower triglyceride levels among those treated with vitamin D. Interestingly, the increase in HDL-C and improvement in triglyceride levels underscore vitamin D’s potential role in enhancing lipid profiles in patients struggling with heart disease.
We also noted that vitamin D treatment didn’t significantly impact CRP levels, which are typically used as a marker for inflammation and heart disease risk. This suggests that while vitamin D might help improve certain lipids, its effects on other markers of heart disease need further investigation.
Overall, our study highlights the potential benefits of vitamin D supplementation as a tool to manage heart disease risk factors, offering a promising option for healthcare professionals working with patients suffering from IHD.
Our findings revealed that participants who received vitamin D supplementation showed notable improvements. Specifically, we observed higher levels of high-density lipoprotein cholesterol (HDL-C)—often referred to as the "good" cholesterol—and lower triglyceride levels among those treated with vitamin D. Interestingly, the increase in HDL-C and improvement in triglyceride levels underscore vitamin D’s potential role in enhancing lipid profiles in patients struggling with heart disease.
We also noted that vitamin D treatment didn’t significantly impact CRP levels, which are typically used as a marker for inflammation and heart disease risk. This suggests that while vitamin D might help improve certain lipids, its effects on other markers of heart disease need further investigation.
Overall, our study highlights the potential benefits of vitamin D supplementation as a tool to manage heart disease risk factors, offering a promising option for healthcare professionals working with patients suffering from IHD.
Read More
7
Vitamin D3 aids heart health
Sirtuin 1 mediates the pro-survival effects of vitamin D in angiotensin II-induced hypertrophy of H9c2 cardiomyoblasts.
Significant relevance to heart disease
We explored the effects of vitamin D3 (VitD) on heart cells, focusing on its ability to counteract changes induced by angiotensin II (Ang II), a compound that can contribute to heart disease. The study involved exposing H9c2 cardiomyoblasts—heart muscle cells—to Ang II alone, and then to both Ang II and VitD to see how VitD might help.
Our findings revealed that while VitD effectively reduced the size of the cells and helped lower markers of hypertrophy (a condition where heart cells enlarge often due to strain), it did not significantly improve cell survival in the absence of a protein called sirtuin-1 (SIRT1). When SIRT1 was inhibited, VitD was unable to protect the cells as it normally would. This suggests that SIRT1 is crucial for the pro-survival benefits of vitamin D.
Importantly, while VitD showed promise in tackling hypertrophy, its protective effects rely heavily on SIRT1 being present. This could lead to new ideas for therapies in heart disease, where activating SIRT1 might enhance the benefits of vitamin D to improve heart health.
Our findings revealed that while VitD effectively reduced the size of the cells and helped lower markers of hypertrophy (a condition where heart cells enlarge often due to strain), it did not significantly improve cell survival in the absence of a protein called sirtuin-1 (SIRT1). When SIRT1 was inhibited, VitD was unable to protect the cells as it normally would. This suggests that SIRT1 is crucial for the pro-survival benefits of vitamin D.
Importantly, while VitD showed promise in tackling hypertrophy, its protective effects rely heavily on SIRT1 being present. This could lead to new ideas for therapies in heart disease, where activating SIRT1 might enhance the benefits of vitamin D to improve heart health.
Read More
3
Vitamin D3's limited heart health effects
Vitamin D and cardiovascular outcomes in multiple sclerosis.
Moderate relevance due to limitations
We explored the connection between vitamin D levels and cardiovascular health in people with multiple sclerosis (pwMS). Specifically, our study examined the effects of vitamin D3 treatment on heart-related outcomes among patients with differing levels of vitamin D. Using data from 70 healthcare organizations over a period of five years, we focused on individuals who had either deficient or adequate vitamin D levels.
Our findings revealed that pwMS with deficient or inadequate vitamin D levels experienced an increased risk of major adverse cardiovascular events (MACE), including heart attacks and strokes. Importantly, while some pwMS received cholecalciferol (a form of vitamin D3) supplementation, this did not significantly reduce their risk of heart problems compared to those with adequate vitamin D levels who were not taking supplements.
Overall, our inquiry shows that simply having adequate vitamin D is crucial, but supplementation with vitamin D3 alone may not confer the expected cardiovascular protective benefits for pwMS. This suggests that more comprehensive strategies may be needed to address heart health in these patients.
Our findings revealed that pwMS with deficient or inadequate vitamin D levels experienced an increased risk of major adverse cardiovascular events (MACE), including heart attacks and strokes. Importantly, while some pwMS received cholecalciferol (a form of vitamin D3) supplementation, this did not significantly reduce their risk of heart problems compared to those with adequate vitamin D levels who were not taking supplements.
Overall, our inquiry shows that simply having adequate vitamin D is crucial, but supplementation with vitamin D3 alone may not confer the expected cardiovascular protective benefits for pwMS. This suggests that more comprehensive strategies may be needed to address heart health in these patients.
Read More
Most Useful Reviews
9
Health improvement
Great Vitamin D with an effective dosage! My vitamin D levels have risen significantly. I take it along with vitamin K2 and calcium. Since starting this regimen, I've noticed fewer illnesses, which is crucial for my autoimmune condition. The jar also has a lovely design!
Read More
9.5
Well tolerated
This vitamin D is well tolerated, even for my sensitive stomach. A daily dose of 5,000 IU is effective for those with D3 deficiency and can assist in treating cardiovascular disease.
Read More
8
Reduced infections
I used to suffer from sinusitis and frequent infections. After starting with Vigantol and then switching to this vitamin D3, my symptoms improved. After 8 months, I had a health check and my levels were at 46, suggesting it works for me. Moreover, the frequency of infections and colds has decreased, supporting my treatment for cardiovascular disease. I recommend it.
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 6 Researches
6.5
8
Vitamin D improves heart disease factors
The Effect of Vitamin D Deficiency Treatment on Lipid Profile and C-reactive Protein in Patients with Ischemic Heart Disease: Double-blind Randomized Clinical Trial.
Direct relevance to cardiovascular health
We conducted a double-blind, randomized clinical trial to see how treating vitamin D deficiency could influence heart health, particularly in patients with ischemic heart disease (IHD). In our study, 44 IHD patients aged 40 to 65 were treated with either vitamin D or a placebo to assess changes in their lipid profiles and C-reactive protein (CRP) levels.
Our findings revealed that participants who received vitamin D supplementation showed notable improvements. Specifically, we observed higher levels of high-density lipoprotein cholesterol (HDL-C)—often referred to as the "good" cholesterol—and lower triglyceride levels among those treated with vitamin D. Interestingly, the increase in HDL-C and improvement in triglyceride levels underscore vitamin D’s potential role in enhancing lipid profiles in patients struggling with heart disease.
We also noted that vitamin D treatment didn’t significantly impact CRP levels, which are typically used as a marker for inflammation and heart disease risk. This suggests that while vitamin D might help improve certain lipids, its effects on other markers of heart disease need further investigation.
Overall, our study highlights the potential benefits of vitamin D supplementation as a tool to manage heart disease risk factors, offering a promising option for healthcare professionals working with patients suffering from IHD.
Our findings revealed that participants who received vitamin D supplementation showed notable improvements. Specifically, we observed higher levels of high-density lipoprotein cholesterol (HDL-C)—often referred to as the "good" cholesterol—and lower triglyceride levels among those treated with vitamin D. Interestingly, the increase in HDL-C and improvement in triglyceride levels underscore vitamin D’s potential role in enhancing lipid profiles in patients struggling with heart disease.
We also noted that vitamin D treatment didn’t significantly impact CRP levels, which are typically used as a marker for inflammation and heart disease risk. This suggests that while vitamin D might help improve certain lipids, its effects on other markers of heart disease need further investigation.
Overall, our study highlights the potential benefits of vitamin D supplementation as a tool to manage heart disease risk factors, offering a promising option for healthcare professionals working with patients suffering from IHD.
Read More
7
Vitamin D3's influence on CVD risk
Perirenal fat differs in patients with chronic kidney disease receiving different vitamin D-based treatments: a preliminary study.
Moderate relevance due to partial findings
We explored how different vitamin D treatments may influence cardiovascular disease (CVD) risk among patients with chronic kidney disease (CKD). Our observational study included 83 CKD patients who were treated with vitamin D or its analogs and had varying histories of CVD. By measuring the thickness of perirenal adipose tissue (PAT) and assessing clinical parameters, we aimed to uncover any links between vitamin D treatment and cardiovascular health.
We found that patients with a history of CVD showed thicker PAT compared to those without such a history. Interestingly, our comparisons among patients receiving different forms of vitamin D revealed that those treated with paricalcitol had less PAT accumulation than those on cholecalciferol or calcitriol. This suggests that the type of vitamin D treatment may play a role in managing CVD risk in CKD patients.
Although our findings indicate differences in PAT thickness related to vitamin D treatment, we did not conduct a controlled trial that would allow us to claim a definitive benefit of vitamin D3 alone on cardiovascular health. It appears that further investigation is necessary to clarify these relationships and understand the mechanisms at play.
We found that patients with a history of CVD showed thicker PAT compared to those without such a history. Interestingly, our comparisons among patients receiving different forms of vitamin D revealed that those treated with paricalcitol had less PAT accumulation than those on cholecalciferol or calcitriol. This suggests that the type of vitamin D treatment may play a role in managing CVD risk in CKD patients.
Although our findings indicate differences in PAT thickness related to vitamin D treatment, we did not conduct a controlled trial that would allow us to claim a definitive benefit of vitamin D3 alone on cardiovascular health. It appears that further investigation is necessary to clarify these relationships and understand the mechanisms at play.
Read More
7
Vitamin D3 aids heart health
Sirtuin 1 mediates the pro-survival effects of vitamin D in angiotensin II-induced hypertrophy of H9c2 cardiomyoblasts.
Significant relevance to heart disease
We explored the effects of vitamin D3 (VitD) on heart cells, focusing on its ability to counteract changes induced by angiotensin II (Ang II), a compound that can contribute to heart disease. The study involved exposing H9c2 cardiomyoblasts—heart muscle cells—to Ang II alone, and then to both Ang II and VitD to see how VitD might help.
Our findings revealed that while VitD effectively reduced the size of the cells and helped lower markers of hypertrophy (a condition where heart cells enlarge often due to strain), it did not significantly improve cell survival in the absence of a protein called sirtuin-1 (SIRT1). When SIRT1 was inhibited, VitD was unable to protect the cells as it normally would. This suggests that SIRT1 is crucial for the pro-survival benefits of vitamin D.
Importantly, while VitD showed promise in tackling hypertrophy, its protective effects rely heavily on SIRT1 being present. This could lead to new ideas for therapies in heart disease, where activating SIRT1 might enhance the benefits of vitamin D to improve heart health.
Our findings revealed that while VitD effectively reduced the size of the cells and helped lower markers of hypertrophy (a condition where heart cells enlarge often due to strain), it did not significantly improve cell survival in the absence of a protein called sirtuin-1 (SIRT1). When SIRT1 was inhibited, VitD was unable to protect the cells as it normally would. This suggests that SIRT1 is crucial for the pro-survival benefits of vitamin D.
Importantly, while VitD showed promise in tackling hypertrophy, its protective effects rely heavily on SIRT1 being present. This could lead to new ideas for therapies in heart disease, where activating SIRT1 might enhance the benefits of vitamin D to improve heart health.
Read More
7
Vascular calcification insights explored
Elabela alleviates cuproptosis and vascular calcification in vitaminD3- overloaded mice via regulation of the PPAR-γ /FDX1 signaling.
Study complexity reduces clarity
In exploring how vitamin D3 influences cardiovascular disease, we conducted experiments with both young and aged mice, who were treated with vitamin D3 or saline to assess its impact on vascular calcification. Out of our findings, it was crucial to note that while vitamin D3 treatments were utilized, we also incorporated Elabela and other compounds, making it challenging to isolate vitamin D3's specific effects on cardiovascular health fully.
Through our study, we observed the potential protective role of Elabela against vascular calcification, particularly acting through pathways that involve PPAR-γ and FDX1 signaling. However, the combination of treatments lacks clarity on the specific benefits of vitamin D3 by itself in managing vascular health. Thus, the data does not present a clear advantage for vitamin D3 in reducing cardiovascular disease risks when considered independently from Elabela.
Overall, our research underlines the complexity of vitamin D3's role in cardiovascular conditions and indicates that more targeted studies are necessary to define its specific contributions clearly.
Through our study, we observed the potential protective role of Elabela against vascular calcification, particularly acting through pathways that involve PPAR-γ and FDX1 signaling. However, the combination of treatments lacks clarity on the specific benefits of vitamin D3 by itself in managing vascular health. Thus, the data does not present a clear advantage for vitamin D3 in reducing cardiovascular disease risks when considered independently from Elabela.
Overall, our research underlines the complexity of vitamin D3's role in cardiovascular conditions and indicates that more targeted studies are necessary to define its specific contributions clearly.
Read More
7
Vitamin D3's cardiovascular association analyzed
[Association of serum 25(OH)D with cardiovascular risk-related indicators: cross-sectional analysis of NHANES].
Depicts moderate relevance to treatment
We explored how serum levels of vitamin D3, specifically 25(OH)D, might influence various indicators related to cardiovascular health. Using data from the National Health and Nutrition Examination Survey (NHANES) spanning 2015 to 2018, we analyzed results from 4,727 adults aged 20 and above.
Our investigation focused on several key factors such as body mass index, high-density lipoprotein cholesterol, systolic blood pressure, and cholesterol levels. The results showed that even a slight increase in vitamin D3 levels was associated with positive changes across these cardiovascular risk factors. For instance, we found that a 1 nmol/L increase in serum 25(OH)D led to small but significant improvements in several indicators.
Notably, the effects varied by gender and age, with women showing greater sensitivity to vitamin D3 levels compared to men, while older adults were less responsive. However, our findings highlighted a complex relationship, revealing nonlinear patterns that suggest additional research is necessary to fully understand these dynamics. While the results display promising associations, they do not confirm that vitamin D3 treatment can directly improve cardiovascular disease outcomes.
Our investigation focused on several key factors such as body mass index, high-density lipoprotein cholesterol, systolic blood pressure, and cholesterol levels. The results showed that even a slight increase in vitamin D3 levels was associated with positive changes across these cardiovascular risk factors. For instance, we found that a 1 nmol/L increase in serum 25(OH)D led to small but significant improvements in several indicators.
Notably, the effects varied by gender and age, with women showing greater sensitivity to vitamin D3 levels compared to men, while older adults were less responsive. However, our findings highlighted a complex relationship, revealing nonlinear patterns that suggest additional research is necessary to fully understand these dynamics. While the results display promising associations, they do not confirm that vitamin D3 treatment can directly improve cardiovascular disease outcomes.
Read More
User Reviews
USERS' SCORE
Good
Based on 8 Reviews
8.5
9.5
Well tolerated
This vitamin D is well tolerated, even for my sensitive stomach. A daily dose of 5,000 IU is effective for those with D3 deficiency and can assist in treating cardiovascular disease.
9.5
Overall wellness
I've been taking this vitamin for over a year, and it has significantly improved my levels and overall well-being. I also buy it for my parents, and they've noticed health improvements too.
9
Health improvement
Great Vitamin D with an effective dosage! My vitamin D levels have risen significantly. I take it along with vitamin K2 and calcium. Since starting this regimen, I've noticed fewer illnesses, which is crucial for my autoimmune condition. The jar also has a lovely design!
8.8
Bone health
Combining vitamin D with K2 is essential to prevent calcium deposits in blood vessels. This combination supports bone health and is beneficial for the cardiovascular system.
8.8
Immune support
Vitamin D3 is crucial for multiple bodily functions, including immune regulation. I've increased my levels from 43.7 to 53.6, and it's vital for cardiovascular health too.
